Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Overview of attention for article published in New England Journal of Medicine, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 4 posts from 2 blogs.

People with advanced endometrial cancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with…

Bookmark 1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9…

In two clinical trials, combining immune checkpoint inhibitors with standard chemotherapy substantially increased how long…

TUESDAY, April 4, 2023 (HealthDay News) — The addition of pembrolizumab to paclitaxel plus carboplatin is associated with…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.